Literature DB >> 12403562

Intracranial neoplasms in children with neurofibromatosis 1.

Tena Rosser1, Roger J Packer.   

Abstract

Neurofibromatosis 1 is associated with an increased risk for the development of benign and malignant tumors involving neural and non-neural tissues. Children as well as adults with neurofibromatosis 1 are affected. Central nervous system neoplasms represent a significant portion of these malignancies and appear primarily in children less than 10 years of age. Optic pathway gliomas and brainstem gliomas are the most common intracranial neoplasms found in neurofibromatosis 1, although there also is an increased incidence of other brain tumors in this population. The majority of these intracranial neoplasms are benign pilocytic astrocytomas, which may behave in a less aggressive manner than histologically identical tumors in non-neurofibromatosis 1 patients. Owing to the indolent nature of these tumors, conservative management with close follow-up is recommended. When intervention is required, conventional treatment with surgery, radiation, or chemotherapy has been used with variable results. The current challenge lies in understanding the pathogenesis of gliomas in neurofibromatosis 1, which may lead to the development of biologically directed therapies with less associated morbidity and mortality for neurofibromatosis 1 as well as non-neurofibromatosis 1 children.

Entities:  

Mesh:

Year:  2002        PMID: 12403562     DOI: 10.1177/088307380201700815

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  16 in total

1.  Brain Tumors in Neurofibromatosis.

Authors:  Deborah R. Gold; Bruce H. Cohen
Journal:  Curr Treat Options Neurol       Date:  2003-05       Impact factor: 3.598

2.  Natural history and management of low-grade glioma in NF-1 children.

Authors:  Pablo Hernáiz Driever; Stephan von Hornstein; Torsten Pietsch; Rolf Kortmann; Monika Warmuth-Metz; Angela Emser; Astrid K Gnekow
Journal:  J Neurooncol       Date:  2010-03-30       Impact factor: 4.130

3.  A multi-institutional study of brainstem gliomas in children with neurofibromatosis type 1.

Authors:  Jasia Mahdi; Amish C Shah; Aimee Sato; Stephanie M Morris; Robert C McKinstry; Robert Listernick; Roger J Packer; Michael J Fisher; David H Gutmann
Journal:  Neurology       Date:  2017-03-22       Impact factor: 9.910

Review 4.  Ophthalmological manifestations in VHL and NF 1: pathological and diagnostic implications.

Authors:  Klaus-Martin Kreusel
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

Review 5.  [Neurofibromatoses].

Authors:  A Zimmer
Journal:  Radiologe       Date:  2013-12       Impact factor: 0.635

6.  Therapeutics for childhood neurofibromatosis type 1 and type 2.

Authors:  Simone L Ardern-Holmes; Kathryn N North
Journal:  Curr Treat Options Neurol       Date:  2011-12       Impact factor: 3.598

7.  Detection and measurement of neurofibromatosis-1 mouse optic glioma in vivo.

Authors:  Debasish Banerjee; Balazs Hegedus; David H Gutmann; Joel R Garbow
Journal:  Neuroimage       Date:  2007-02-23       Impact factor: 6.556

8.  Neurofibromatosis type 1 and high-grade tumors of the central nervous system.

Authors:  Amy Rosenfeld; Robert Listernick; Joel Charrow; Stewart Goldman
Journal:  Childs Nerv Syst       Date:  2009-11-25       Impact factor: 1.475

9.  Histologically benign, clinically aggressive: Progressive non-optic pathway pilocytic astrocytomas in adults with NF1.

Authors:  Roy E Strowd; Fausto J Rodriguez; Roger E McLendon; James J Vredenburgh; Aaron B Chance; George Jallo; Alessandro Olivi; Edward S Ahn; Jaishri O Blakeley
Journal:  Am J Med Genet A       Date:  2016-03-14       Impact factor: 2.802

10.  Visual outcome of a cohort of children with neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology program.

Authors:  Paola Dalla Via; Enrico Opocher; Maria Luisa Pinello; Milena Calderone; Elisabetta Viscardi; Maurizio Clementi; Pier Antonio Battistella; Anna Maria Laverda; Liviana Da Dalt; Giorgio Perilongo
Journal:  Neuro Oncol       Date:  2007-08-17       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.